Cellgen Diagnostics is a privately held molecular diagnostics company that is developing a new class of diagnostics called PHARMACODYNAMICS (PD), which can be leveraged across multiple disease states throughout the continuum of patient healthcare. Pharmacodynamics differs from Pharmacogenomics (PG) in that pharmacogenomics measures how drugs will metabolize in the body. Cellgen’s pharmacodynamics platform, on the other hand, offers a dynamic measurement to predict the body’s response to a particular drug based on a genetic expression of a multi-parameter biomarker signature.
Current tissue-based molecular test methodologies limit personalized medicine to patients with actionable DNA mutations or aberrations, which only represents approximately 30% of the population. Blood-based diagnostics, on the other hand, are aggressively addressing the barriers of adoption and will help to revolutionize disease research, patient treatment, and survivor care. Cellgen’s therapeutic guidance platform will incorporate machine learning to deliver intelligent quantitative and actionable results to clinicians in 2 hours. Cellgen is poised to take advantage of the projected multibillion-dollar market growth in the field of personalized medicine by partnering with clinicians and payers to develop predictive tests that would enhance patient outcomes, avoid trial and error prescribing and reduce toxicity risk. Located in beautiful San Diego, CA, Cellgen licensed its original technology from the